Mr. Masse is correct. Currently, section 21.09 of the Patent Act states that a CAMR authorization is valid for two years from the date of the grant. That was reflective of several WTO requirements in the decision, including paragraph 2(c) of the waiver, which requires a country that authorizes the export--so a country like Canada--of a pharmaceutical product under its regime to notify the WTO of the quantities for which the authorization has been granted and the duration. Reflective of that and other WTO requirements, section 21.09 of the Patent Act presently describes the duration of an export, and it says that it would be valid for two years from the date of grant.
Clause 9 of Bill C-393 would delete this section altogether. It's a short section, but it is an important section in the regime.